Genomictree Inc.
228760
Pozycja w akcjach
#18738
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Cena akcji
$7.00
Kapitalizacja rynkowa
$171.81M
Zmiana (1 dzień)
6.44%
Zmiana (1 rok)
-47.27%
Kraj
KR
Handel Genomictree Inc. (228760)
Kategoria
Healthcare
Historia ceny akcji dla Genomictree Inc. (228760)
Najwyższa cena zamknięcia: $7.30 dnia 2026-10-01
Najniższa cena zamknięcia: $3.98 dnia 2017-04-01
Najniższa cena zamknięcia: $3.98 dnia 2017-04-01
Historia cen akcji firmy Genomictree Inc. od 2017 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | -34.69% |
| 2025 | 31.68% |
| 2024 | 6.73% |
| 2023 | 91.06% |
| 2022 | -34.74% |
| 2021 | -21.56% |
| 2020 | -30.26% |
| 2019 | -19.05% |
| 2018 | 267.23% |
| 2017 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $536.73 | 25.86% |
US
|
|
| $225.94 | 741.49% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $878.85 | 7.94% |
NL
|
